Silverarc Capital Management LLC Buys 219,344 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Silverarc Capital Management LLC raised its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 24.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,120,473 shares of the company's stock after purchasing an additional 219,344 shares during the period. UroGen Pharma accounts for approximately 2.6% of Silverarc Capital Management LLC's holdings, making the stock its 13th biggest position. Silverarc Capital Management LLC owned 4.78% of UroGen Pharma worth $11,933,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in URGN. Rosalind Advisors Inc. bought a new position in UroGen Pharma during the fourth quarter valued at approximately $9,266,000. State Street Corp boosted its position in shares of UroGen Pharma by 5.9% during the 3rd quarter. State Street Corp now owns 769,583 shares of the company's stock valued at $9,774,000 after acquiring an additional 42,907 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of UroGen Pharma by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after acquiring an additional 6,265 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of UroGen Pharma by 2.7% in the fourth quarter. Wells Fargo & Company MN now owns 221,540 shares of the company's stock valued at $2,359,000 after purchasing an additional 5,801 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in UroGen Pharma by 751.5% in the fourth quarter. Alliancebernstein L.P. now owns 199,259 shares of the company's stock worth $2,122,000 after purchasing an additional 175,859 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on URGN shares. The Goldman Sachs Group dropped their price objective on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Scotiabank initiated coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target for the company. HC Wainwright reduced their price objective on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, March 10th. Finally, LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.86.

Insider Activity at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company's stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Schoenberg sold 4,551 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now owns 145,666 shares of the company's stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

UroGen Pharma Stock Performance

Shares of UroGen Pharma stock opened at $9.66 on Tuesday. UroGen Pharma Ltd. has a 52 week low of $8.94 and a 52 week high of $20.70. The company has a market capitalization of $445.27 million, a PE ratio of -3.07 and a beta of 0.80. The stock's fifty day moving average is $10.48 and its two-hundred day moving average is $11.15. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. As a group, analysts expect that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.